Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeh, Ming-Lun | en_US |
dc.contributor.author | Huang, Jee-Fu | en_US |
dc.contributor.author | Dai, Chia-Yen | en_US |
dc.contributor.author | Yu, Ming-Lung | en_US |
dc.contributor.author | Chuang, Wan-Long | en_US |
dc.date.accessioned | 2019-12-13T01:12:24Z | - |
dc.date.available | 2019-12-13T01:12:24Z | - |
dc.date.issued | 2019-10-03 | en_US |
dc.identifier.issn | 1742-5255 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1080/17425255.2019.1678584 | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/153246 | - |
dc.description.abstract | Introduction: Interferon (IFN) had both antiviral and immunomodulatory effects, and was one of the approved treatments for hepatitis B virus (HBV). Herein, we reviewed the pharmacokinetics and pharmacodynamics of pegylated IFN-? (PegIFN-?) for the treatment of HBV. Areas covered: The steady-state serum levels of PegIFN-? were reached within 5 to 8?weeks, and the week 48 mean trough concentrations were approximately 2-fold higher than week 1. There was also no difference of the pharmacokinetics in male or female, healthy volunteers or patients with hepatitis B or C infection. PegIFN-? did not affect the metabolism of the cytochrome P450 (CYP) isozymes, except inhibition of CYP1A2. There was also no pharmacokinetic interaction between PegIFN-? and HBV nucleot(s)ide analogues (NUCs). Forty-eight weeks of PegIFN-? achieved 32% of HBeAg seroconversion, 32-43% of HBV DNA suppression, 41-59% of ALT normalization, and 3% of HBsAg seroconversion rate with a post-treatment durable response up to 80% in the initial responders. Expert opinion: On-treatment HBsAg titer guided the treatment of HBV with PegIFN-?. The recommendation of PegIFN-? and NUC combination or switch remained controversial. New immunotherapeutic agents are now in development. Although, PegIFN-? should continue to play a role in the treatment of HBV. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | Interferon | en_US |
dc.subject | Pegylated interferon | en_US |
dc.subject | Pharmacokinetic | en_US |
dc.subject | Pharmacodynamic | en_US |
dc.subject | Mechanism | en_US |
dc.title | Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1080/17425255.2019.1678584 | en_US |
dc.identifier.journal | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | en_US |
dc.citation.volume | 15 | en_US |
dc.citation.issue | 10 | en_US |
dc.citation.spage | 779 | en_US |
dc.citation.epage | 785 | en_US |
dc.contributor.department | 生物科技學院 | zh_TW |
dc.contributor.department | 生醫工程研究所 | zh_TW |
dc.contributor.department | College of Biological Science and Technology | en_US |
dc.contributor.department | Institute of Biomedical Engineering | en_US |
dc.identifier.wosnumber | WOS:000491298100002 | en_US |
dc.citation.woscount | 0 | en_US |
Appears in Collections: | Articles |